Pfizer, Inc. · NYSE:PFE
Pfizer — Barclays Capital 2011 Global Healthcare Conference
14 slides from Pfizer's conference presentation, Mar 17, 2011
Slide 1: Pfizer Worldwide Research & Development
Pfizer Worldwide Research & Development Presentation by Mikael Dolsten, M.D., PhD. Barclays Capital 2011 Global Healthcare Conference March 17, 2011
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2010 Annual Repo
Slide 3: Pfizer R&D: Important Progress 2009-2011
Pfizer R&D: Important Progress 2009-2011 A Strengthened R&D Organization Centered on pipeline delivery Applying a breadth of science and technology Improving decision-making and clinical development of candidates Delivering smarter, more authentic integration of science and business Establishin
Slide 4: A Comprehensive Turn-Around Strategy is Underway
A Comprehensive Turn-Around Strategy is Underway Focused on Three Horizons to Drive Sustained Progress y Precision Medicine Horizon 3 y Networked, interactive R&D R&D Ecosystem of the Future y Breakthrough productivity y Next generation therapeutics Horizon 2 y Open and external innovation Innovate
Slide 5: Recent Moves to Accelerate Our Progress
Recent Moves to Accelerate Our Progress Creating an 1 engine for Creating greater Improving output and focus to strengthen our sustainable reducing costs to innovation scientific core drive productivity 2 Probability Quality of Driving competitive of Success Output advantage through strategic extern
Slide 6: Today's Key Registration Assets and Potential Key Near-Term Submissions
___________________________________ DELIVER THE PORTFOLIO Today’s Key Registration Assets …and Potential Key Near-Term Submissions In Registration Near Term Filing Opportunities Prevenar 13 Adult (Pneumococcal Disease) Apixaban (Atrial Fibrillation) Axitinib (Renal Cell Carcinoma) Pristiq (Vasomotor
Slide 7: Today's Rich Phase 3 Portfolio
Today’s Rich Phase 3 Portfolio y Bapineuzumab – Alzheimer’s Disease y Tofacitinib – Rheumatoid y Bazedoxifene-conjugated estrogens Arthritis (Aprela) – Menopausal Vasomotor y Zithromax / chloro – Malaria Symptoms y Tanezumab – OA Pain (on 13 y Axitinib – Renal Cell Carcinoma clinical hold) NMEs y Cr
Slide 8: Early to Mid-Stage Pipeline Shapes the Future
Early to Mid-Stage Pipeline Shapes the Future Immunology & • Strong pipeline of anti-inflammatory drugs across multiple disease areas Inflammation – e.g., anti-IL21 receptor, anti-madcam antibody and anti-TNF nanobody • Growing diabetes clinical pipeline CVMED – e.g., SGLT2 inhibitor, Glucokinase ac
Slide 9: Next Generation Therapeutics: Inotuzumab
________________________________________ INNOVATE NEW CAPABILITIES Next Generation Therapeutics: Inotuzumab Specific mAb-like target binding allows precise delivery to cancer cells Click to edit Master text styles LINKER Second level Calicheamicin Third level Calicheamicin CMC-544 Internalized Linke
Slide 10: Pfizer's Open Innovation Model: Centers for Therapeutic Innovation
Pfizer’s Open Innovation Model: Centers for Therapeutic Innovation (CTI) Click to edit Master text styles Second level Third level Fourth level Fifth level NYC – East River Science Park Agreements signed with: • NYU Langone Medical Center UCSF • Rockefeller University Hospital UCSF agreement complet
Slide 11: What is Precision Medicine?
______________________________________________ R&D ECOSYSTEM OF THE FUTURE What is “Precision Medicine”? Click to edit Master text styles Precision Medicine: Right Target, Right Drug(s), Right Patient Second level Medicines targeting patient segments that Third will have level an optimal response to
Slide 12: Precision Medicine Expected to Drive Improved Drug Development and Commercial Advantage
Precision Medicine Expected to Drive Improved Drug Development and Commercial Advantage Click to edit Master text styles Second level Third level Fourth level Fifth level 11
Slide 13: Examples of Precision Medicine Approaches by Pfizer
Examples of Precision Medicine Approaches by Pfizer Drug/Target: Click to edit Master text styles RN-316/PCSK9 Targeted Patients: Drug/Target: Second level Hypercholesteremic patients unresponsive to statins - many will be FH pts Drug/Target: PF-04991532 Crizotinib/Anaplastic Lymphoma Kinase Third l
Slide 14: Q&A
Q&A
Pfizer — Barclays Capital 2011 Global Healthcare Conference on 6ix